(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 October 2013 (10.10.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/152165 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61K 31/44* (2006.01)
A61P 35/00 (2006.01) *A61K 31/519* (2006.01)

(21) International Application Number:
PCT/US2013/035231

(22) International Filing Date:
4 April 2013 (04.04.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/621,252	6 April 2012 (06.04.2012)	US
1351158	12 February 2013 (12.02.2013)	FR
61/771,457	1 March 2013 (01.03.2013)	US

(71) Applicants: **SANOFI** [FR/FR]; c/o Sanofi, 54 rue La Boétie, F-75013 Paris (FR). **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors; and
(71) Applicants *(for US only)*: **HSU, Karl** [US/US]; c/o Sanofi US, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **LAGER, Joanne** [US/US]; c/o Sanofi US, 55 Corporate Drive, Mail Stop: 55A-505A, Bridgewater, New Jersey 08807 (US). **OGDEN, Janet Anne Meurer** [US/US]; c/o Merck Patent GmbH, Frankfurterstrasse 250, 64293 Darmstadt (DE).

(74) Agents: **SZCZEPANIK, Ann Marie** et al.; Sanofi U.S., 55 Corporate Drive, Mail Code 55A-505A, Bridgewater, New Jersey 08807 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

[Continued on next page]

(54) **Title**: METHODS FOR TREATING CANCER USING PI3K INHIBITOR AND MEK INHIBITOR




FIG. 1

(57) **Abstract**: Methods of treating patients with cancer are provided, wherein the methods comprise administering to the patient an effective amount of a MEK inhibitor and an effective amount of a PI3K inhibitor. Compositions in which the MEK and PI3K inhibitors are combined also are described.

WO 2013/152165 A1

Published:

— *with international search report (Art. 21(3))*